CANCER INVESTIGATION Journal
Overview
publication venue for
- First-Line Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous KRAS Wild Type (WT) Non-Small-Cell Lung Cancer (NSCLC). 35:541-546. 2017
- A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers. 34:213-219. 2016
- A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer. 28:208-215. 2010
- A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with carboplatin and etoposide in extensive stage small cell lung cancer. 23:511-519. 2005
- 96-hour paclitaxel infusions: At least 93 hours too long 2003
- Intracellular flow cytometric analysis of primary cultured breast tumor cells. 20:340-347. 2002
- Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: Report of a phase II trial. 17:181-188. 1999
- IMMUNOTOXINS IN THE THERAPY OF LEUKEMIAS AND LYMPHOMAS. 9:211-219. 1991
Research
category
- ONCOLOGY Web of Science Category
Identity
International Standard Serial Number (ISSN)
- 0735-7907
Electronic International Standard Serial Number (EISSN)
- 1532-4192
Other
journal abbreviation
- CANCER INVEST